Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat

Transplantation

Volumn 87, Issue 9, 2009, Pages 1290-1299

  Wittmann, Sandra ^a   Daniel, Christoph ^a   Stief, Andrea ^a   Vogelbacher, Regina ^a   Amann, Kerstin ^a   Hugo, Christian ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Calcineurin phosphatase; Cyclosporine.; Diabetic nephropathy; MTOR; Sirolimus

Indexed keywords

CD5 ANTIGEN; CREATININE; CYCLOSPORIN A; DESMIN; FIBRONECTIN; GLUCOSE; LAMININ; PLACEBO; RAPAMYCIN; SMAD2 PROTEIN; SMAD3 PROTEIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; UREA; VASCULOTROPIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LOSS; CELL PROTECTION; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; LONG TERM CARE; MALE; NEPHRITIS; NONHUMAN; PERIODIC ACID SCHIFF STAIN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STREPTOZOCIN DIABETES; UREA BLOOD LEVEL; WESTERN BLOTTING;

ANIMALS; CYCLOSPORINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DNA PRIMERS; FIBRONECTINS; IMMUNOSUPPRESSIVE AGENTS; LAMININ; MALE; NEPHROGENIC FIBROSING DERMOPATHY; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67649616517     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a192bd     Document Type: Article

References (43)

1. Estacio RO, Schrier RW. Diabetic nephropathy: Pathogenesis, diagnosis, and prevention of progression. Adv Intern Med 2001; 46: 359.
2. Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: As deleterious as non-transplant-associated diabetes? Transplantation 1998; 65: 380.
3. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: New insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384.
4. Remuzzi G, Perico N. Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int Suppl 1995; 52: S70.
5. Paul LC, de Fijter JH. Cyclosporine-induced renal dysfunction. Transplant Proc 2004; 36(2 suppl): 224S.
6. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation1997; 64: 36.
7. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002; 11: 1845.
8. Sehgal SN, Camardo JS, Scarola JA, et al. Rapamycin (sirolimus, rapamune). Curr Opin Nephrol Hypertens 1995; 4: 482.
9. Araki M, Flechner SM, Ismail HR, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006; 81: 335.
10. Sakaguchi M, Isono M, Isshiki K, et al. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 2006; 340: 296.
11. Lloberas N, Cruzado JM, Franquesa M, et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17: 1395.
12. Yang Y, Wang J, Qin L, et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 2007; 27:495.
13. Gooch JL, Barnes JL, Garcia S, et al. Calcineurin is activated in diabetes and is required for glomerular hypertrophy and ECM accumulation. Am J Physiol Renal Physiol 2003; 284: F144.
14. Nangaku M, Alpers CE, Pippin J, et al. A new model of renal microvascular endothelial injury. Kidney Int 1997; 52: 182.
15. Iruela-Arispe L, Gordon K, Hugo C, et al. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 1995; 147: 1715.
16. Hermann P, Poschmann G, Bolliger S, et al. Mercuric chloride-induced glomerulopathy in BN-rats: Application to preclinical drug testing. Transplant Proc 1993; 25: 2826.
17. Riley SG, Steadman R, Williams JD, et al. Augmentation of kidney injury by basic fibroblast growth factor or platelet-derived growth factor does not induce progressive diabetic nephropathy in the Goto Kakizaki model of non-insulin-dependent diabetes. J Lab Clin Med 1999; 134: 304.
18. Amann K, Koch A, Hofstetter J, et al. Glomerulosclerosis and progression: Effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 2001; 60: 1309.
19. Wittmann S, Daniel C, Braun A, et al. The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat. Nephron Exp Nephrol 2008; 108: e45.
20. Jacobi J, Porst M, Cordasic N, et al. Subtotal nephrectomy impairs ischemia-induced angiogenesis and hindlimb re-perfusion in rats. Kidney Int 2006; 69: 2013.
21. Coimbra TM, Janssen U, Grone HJ, et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000; 57: 167.
22. Gross ML, Ritz E, Schoof A, et al. Renal damage in the SHR/N-cp type 2 diabetes model: Comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Invest 2003; 83: 1267.
23. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: An explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 2007; 292: F1665.
24. Sassy-Prigent C, Heudes D, Mandet C, et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes2000; 49: 466.
25. Utimura R, Fujihara CK, Mattar AL, et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003; 63: 209.
26. Gooch JL, Pergola PE, Guler RL, et al. Differential expression of calcineurin A isoforms in the diabetic kidney. J Am Soc Nephrol 2004; 15: 1421.
27. Fox R, Nhan TQ, Law GL, et al. PSGL-1 andmTORregulate translation of ROCK-1 and physiological functions of macrophages.EMBOJ 2007; 26: 505.
28. Sharma K, Jin Y, Guo J, et al. Neutralization of TGF-beta by anti-TGFbeta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes1996; 45: 522.
29. Nicholas SB. Advances in pathogenetic mechanisms of diabetic nephropathy. Cell Mol Biol (Noisy-le-grand) 2003; 49: 1319.
30. Ziyadeh FN. Mediators of diabetic renal disease: The case for TGF-beta as the major mediator. J Am Soc Nephrol 2004; 15(suppl 1): S55.
31. de Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993.
32. Kang DH, Hughes J, Mazzali M, et al. Impaired angiogenesis in the remnant kidney model. II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001; 12: 1448.
33. Shimizu A, Kitamura H, Masuda Y, et al. Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis. Am J Pathol 1997; 151: 1231.
34. Daniel C, Renders L, Amann K, et al. Mechanisms of everolimusinduced glomerulosclerosis after glomerular injury in the rat. Am J Transplant 2005; 5: 2849.
35. Keller K, Daniel C, Schocklmann H, et al. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol Dial Transplant 2006; 21: 2724.
36. Mundel P, Heid HW, Mundel TM, et al. Synaptopodin: An actinassociated protein in telencephalic dendrites and renal podocytes. J Cell Biol 1997; 139: 193.
37. Laugharne M, Cross S, Richards S, et al. Sirolimus toxicity and vascular endothelial growth factor release from islet and renal cell lines. Transplantation2007; 83: 1635.
38. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869.
39. Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2: 326.
40. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707.
41. Hohenstein B, Hausknecht B, Boehmer K, et al. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 2006; 69: 1654.
42. Gooch JL, Gorin Y, Zhang BX, et al. Involvement of calcineurin in transforming growth factor-beta-mediated regulation of extracellular matrix accumulation. J Biol Chem 2004; 279: 15561.
43. Islam M, Burke JF Jr, McGowan TA, et al. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int 2001; 59: 498.